Intuitive Surgical Expands European Operations with Da Vinci and Ion Distribution Business Acquisition
Money

Intuitive Surgical Expands European Operations with Da Vinci and Ion Distribution Business Acquisition

authorBy T. Harv Eker
DateMar 10, 2026
Read time2 min

Intuitive Surgical, Inc. has finalized its acquisition of the distribution operations for its da Vinci and Ion product lines from ab medica, Abex, and Excelencia Robótica. This strategic move, announced on March 2, integrates the acquired businesses into Intuitive Surgical's European commercial and marketing framework, marking a significant step in the company's direct operational expansion across Europe. This development is expected to bolster Intuitive Surgical's presence in the European market, particularly in countries like Italy, Spain, and Portugal, where a substantial number of da Vinci surgical systems are already in use.

The acquisition allows Intuitive Surgical to assume full ownership of the da Vinci and Ion distribution channels previously managed by its partners. By incorporating these operations directly, the company aims to streamline its sales, marketing, and support services in key European regions. This integration is crucial for enhancing customer relationships and optimizing the delivery of its robotic-assisted surgical and endoluminal systems.

As of late 2025, the combined installed base of da Vinci surgical systems across Italy, Spain, and Portugal had surpassed 470 units, demonstrating a strong existing market presence. Furthermore, the Ion endoluminal system, another innovative product from Intuitive Surgical, has recently been introduced in both Italy and Spain, indicating a growing portfolio and expanding market reach within Europe.

In a separate but related development, Intuitive Surgical's da Vinci 5 system received clearance from the U.S. Food and Drug Administration (FDA) on January 26. This clearance specifically covers certain complex cardiac procedures, including mitral valve repair and internal mammary artery (IMA) mobilization for cardiac revascularization. This regulatory approval underscores the continuous innovation and clinical versatility of Intuitive Surgical's technology, broadening its applicability in advanced surgical interventions.

Intuitive Surgical, Inc. is recognized for its comprehensive suite of products and services designed to provide robotic-assisted surgical solutions and support for minimally invasive care. Its core offerings include the highly acclaimed da Vinci Surgical systems and the innovative Ion Endoluminal platform, which together form an extensive ecosystem aimed at transforming surgical practices and improving patient outcomes globally.

The completed acquisition and the recent FDA clearance highlight Intuitive Surgical's commitment to growth and innovation in the global medical technology sector. By strengthening its direct operational footprint in Europe and expanding the clinical applications of its advanced surgical systems, Intuitive Surgical is poised to further solidify its leadership in robotic-assisted surgery, contributing to advancements in patient care and surgical efficiency worldwide.

More Articles
BofA Raises Price Target for TJX Companies, Citing Strong Performance and Growth Potential
Bank of America (BofA) has increased its price target for The TJX Companies, Inc. (TJX) from $168 to $175, maintaining a Buy rating. This adjustment follows TJX's impressive fourth-quarter financial results, which exceeded expectations in both sales and margins. The firm anticipates continued market share gains and benefits from customer trade-downs, reinforcing a positive outlook for the off-price retailer.
By Ramit SethiMar 10, 2026
China's Ambitious AI Strategy to Drive Economic Growth and Job Creation
China is heavily investing in artificial intelligence (AI) to revitalize its economy and create jobs, especially for its aging workforce and new university graduates. Despite global concerns about AI's impact on employment, Chinese policymakers are optimistic, highlighting AI's potential to generate new opportunities and boost productivity. This strategy aims to counter economic slowdown and adapt to evolving labor market dynamics, with significant focus on education and industry restructuring.
By JL CollinsMar 10, 2026
BofA Initiates Buy Coverage for Mastercard, Citing AI Advancements
Bank of America has recommenced coverage of Mastercard, assigning a 'Buy' rating and a $700 price target. This decision follows Mastercard's successful pilot program in Malaysia, demonstrating authenticated AI-powered transactions for everyday tasks like booking transportation. The initiative highlights the company's commitment to leveraging artificial intelligence for secure and seamless payment solutions.
By Natalie PaceMar 10, 2026
MicroStrategy's Bitcoin Strategy and Future Prospects
MicroStrategy (MSTR) is highlighted as a potentially lucrative long-term investment, primarily due to its substantial Bitcoin holdings. Despite a recent price target cut by Clear Street due to lower Bitcoin prices, the firm maintains a 'Buy' rating, emphasizing MicroStrategy's strong position in the digital asset treasury sector. The company continues to accumulate Bitcoin, reinforcing its commitment to the cryptocurrency. This analysis suggests MSTR could be a key player in wealth generation over the next decade.
By T. Harv EkerMar 10, 2026
BofA Views Open AI's Shift as Beneficial for Walmart (WMT)
Bank of America (BofA) has indicated that recent developments from OpenAI are positive for Walmart Inc. (WMT). This perspective arises from OpenAI's decision to scale back its direct shopping integration within ChatGPT. BofA suggests this shift could foster an integrated commerce solution akin to Walmart's existing collaboration with Google's Gemini. The firm has reiterated a 'Buy' rating for WMT, setting a price target of $150, anticipating increased search visibility for Walmart's 'Sparky' platform due to its diverse product range and competitive pricing.
By Ramit SethiMar 10, 2026